WHO

The World Health Organization (WHO) continually updates a “living guideline” on drug treatments for COVID-19. The latest update strongly recommends an arthritis drug called baricitinib for patients with severe or critical disease. The recommendation follows a review by an expert panel of the latest evidence from clinical trials. The recommendation follows a review by an expert panel of the latest evidence from clinical trials. The recommendation follows a review by an expert panel of the latest. The update also recommends the monoclonal antibody sotrovimab for individuals who do not have severe COVID-19 but are at high risk of hospitalization. The WHO has strongly recommended that doctors use an arthritis drug called baricitinib to treat people with severe or critical COVID-19. The drug belongs to a class of medications known as Janus kinase (JAK) inhibitors, which block the activity of immune signaling molecules called cytokines. The update also recommends the monoclonal antibody sotrovimab for individuals who do not have severe COVID-19 but are at high risk of hospitalization. The WHO has strongly recommended that doctors use an arthritis drug called baricitinib to treat people with severe or critical COVID-19. The drug belongs to a class of medications known as Janus kinase (JAK) inhibitors, which block the activity of immune signaling molecules called cytokines. The update also recommends the monoclonal antibody sotrovimab for individuals who do not have severe COVID-19 but are at high risk of hospitalization. The WHO has strongly recommended that doctors use an arthritis drug called baricitinib to treat people with severe or critical COVID-19. The drug belongs to a class of medications known as Janus kinase (JAK) inhibitors, which block the activity of immune signaling molecules called cytokines.The update also recommends the monoclonal antibody sotrovimab for individuals who do not have severe COVID-19 but are at high risk of hospitalization. The WHO has strongly recommended that doctors use an arthritis drug called baricitinib to treat people with severe or critical COVID-19. The drug belongs to a class of medications known as Janus kinase (JAK) inhibitors, which block the activity of immune signaling molecules called cytokines.